[PET as a tool in pharmacologic development]
Related Experiment Video
Updated: Oct 28, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
Published on: October 25, 2024
M Bergström1, P Hartvig, B Långström
1Uppsala Universitet PET-centrum.
Abstract:
Positron emission tomography (PET) allows the in vivo recording of tracer compounds with respect to anatomical distribution, time course and absolute concentration. These features has proven of great value in drug development, especially in the phase of early clinical trials. PET can be used to assess the tissue kinetics of a new drug, or to evaluate a drugs interaction with a target system and thereby aid in decisions regarding dosing regimes.
Related Concept Videos
Drug Discovery: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacodynamic Models: Overview
Pharmacogenomics: Identification of New Drug Targets
